Download Citation
Article Source:
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
Okabe S,
Tauchi T,
Kimura S,
Maekawa T,
Kitahara T,
et al.
(2014)
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia.
PLOS ONE 9(2): e89080.
https://doi.org/10.1371/journal.pone.0089080